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ABSTRACT 
This article reviews comprehensively the spectrum of diseases (aspergillosis) caused by Aspergillus spp, the commonest 
pathogenic form being the A.fumigatus. Aspergilus spp are ubiguitous in the environment and the respiratory tract is the 
portal of entry in most cases. Aspergillosis is associated with significant mortality and morbidity, the prevalence appears to 
be on the increase. About 10million people are at risk of aspergillosis, and 50% would die even with treatment. 
Immunodeficiency, especially neutropenia is central to the pathogenesis of aspergillosis. Diseases caused by A. fumigatus 
include;1) Invasive aspergillosis seen mostly in  stem cell and organ transplant recipients, patients with haematological 
malignancies, cancer patients on chemotherapy and patients with AIDS. Invasive aspergillosis is life threatening, it affects 
the lungs and sinuses but could disseminate to affect the CNS, eye, skin and kidney. 2) Chronic pulmonary Aspergillosis 
occurs in the setting of previous cavitatry lung disease, most commonly tuberculous infections. 3) Allergic 
bronchopulmonary aspergillosis (ABPA) affects people with asthma and cystic fibrosis. A. fumigatus is also implicated in 
the exacerbation of asthma. The clinical symptoms of aspergillosis depend on the type and the systems affected; respiratory 
symptoms are more common as the respiratory tract is disproportionately affected in aspergillosis. Diagnostic features and 
treatment also depends on the type of aspergillosis. Diagnostic testing for aspergillosis includes radiologic tests, culture 
tests, galactomannan testing in body fluids, immunologic tests to detectAspergilus -specific immunoglobulins. Treatment 
modalities include surgery, use of antifungals and immunomodulatory therapy with cytokines.  
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RÉSUMÉ  
Ce document, comprehensivement, fait un compte rendu du spectre des maladies (aspergillose) causées par Aspergillus 
spp.,la plus courante de la forme pathogénique était le A. fumigatus . L’Aspergillus sppestomniprésent dans 
l’environnement et dans la plupart des cas, les voies respiratoires sont les portails d’entrée. L’aspergillose est associe à un 
significatif de mortalités et morbidité, la prévalenceparait d’être en augmentation. A peu près 10 million des personnes sont 
en danger d’aspergillose et 50% mourrait  même avec le traitement, déficience immunologique en particulierneutropénie 
est centrale àla pathogenèse de l’aspergillose. Les maladies causées par A. fumigatuscomprennent : 
1. L’aspergillose invasive qui est trouvé principalement dans les cellules souches et des receveurs de greffes 
d’organes, les maladies avec les magnites hématologiques, les patients cancéreux sous chimiothérapie et les 
patients atteints du SIDA. L’aspergillose invasive est dangereuse pour la vie. Il affecte les poumons et les sinus, 
mais pourrait diffuser à affecter le système nerveux central, l’œil, la peau et le rein. 
2. L’aspergillose pulmonaire chronique se produit dans le cadre de la malade de poumon précédente, fréquemment 
les infections tuberculeuses. 
3. L’aspergillose broncho – pulmonaire allergique (ABPA) affecte les gens atteints d’asthme et mucoviscidose. 
L’A.fumigatus est aussi compris dans l’exacerbation d’asthme. 
Le symptôme clinique d’aspergillose dépend du type et les systèmesaffectés ; les symptômes respiratoires sont plus 
courants la voie respiratoire est affectée de manière disproportionnée dans l’aspergillose. Les caractéristiques 
diagnostiques et traitement dépendent aussi du type d’aspergillose. L’analyse diagnostique pour l’aspergillose comprend 




l’Aspergillus – immunoglobuline spécifique. Les modalités de traitement comprennent la chirurgie, l’usage des 
antifongiques et  la thérapie avec des cytokines immuno modulatrices. 
 
1. INTRODUCTION 
Fungal  infections  have  become  very  prevalent  
with  associated  increase  in  mortality  and 
morbidity. This is especially so for life-threatening 
invasive fungal infections as a result of increase in 
immunodeficiency disorders such acquired 
immune deficiency syndrome (AIDS), cancer and 
cancer treatment, and immunosuppressive therapy 
following transplantation. The result of these is an 
increased risk of invasive aspergillosis which has a 
mortality of 30% even with treatment [1,2].  
Aspergillus also complicates other chronic medical 
conditions; allergic bronchopulmonary aspergillosis 
affects people with   asthma and cystic fibrosis 
while chronic pulmonary aspergillosis occurs in the 
setting of previous tuberculosis infection.  
Aspergilli are saprophytic fungi found worldwide in 
soil and decomposing vegetable materials. There 
are over  350 accepted species  of  Aspergillus,  and  
the  commonest  disease-causing  species  is    
A.fumigatus, followed  by  the  A. flavus. Other 
disease-causing species include A. amstelodani,A. 
terreus,A. niger,A. avenaceus, and A.nidulans [3]. A. 
fumigatus  is  fast  growing and  sporulates  
abundantly,  and  the  spores  or  conidia  are  
released  into  the  environment.  The  conidia  is  
small(about  2-3um in diameter) , and  can  
withstand  extreme  atmospheric condition because 
of  their outer protein coat being hydrophobic. The 
fungus is thermophilic; it can grow at temperatures 
of up to 770C, but grows best at ~ 370C. 
The respiratory system is disproportionately 
affected by deep-seated fungal infections. A. 
fumigatus is the most prevalent airborne fungal 
pathogen[4]. Aspergillus spp. cause a wide spectrum 
of pulmonary infections including acute invasive, 
chronic and allergic, as well as implantation disease 
such as fungal keratitis.  This review highlightsthe 
pathogenesis, risk factors, clinical features, 
diagnosis and treatment of diseases caused by A. 
fumigatus as reported in literature. 
2. VIRULENCE FACTORS OF 
A.FUMIGATUS 
The ability of fungi to cause disease and their 
virulence factors are borne out of strategies to 
overcome and survive in the harsh environment of 
the host. Primary pathogens cause disease in 
immunocompetent hosts; A. fumigatus is an 
opportunistic pathogenand cause disease in 
immunocompromised persons. This distinction 
however, is not clear cut, as primary pathogens 
such as C. immitis may cause virulent disease in 
immunocompromised persons and opportunistic 
fungi such asC. neoformans may occasionally cause 
disease in immunocompetent persons.  
A .fumigatusis able to cause disease by a number of 
virulence factors. These factors include structures 
(adhesins) that enable them to adhere to tissues so 
as to avoid being cleared or swept away by ciliary 
movement or mucous. Conidia of A.fumigatus are 
covered with hydrophobic proteins known as 
rodlets. These rodlet proteins are encoded for by 
RODA and RODB genes and, mediate adhesion of 
the conidia to albumin and collagen. Receptors on 
the surface of hyphae include galactomannan and 
chitin of A. fumigatus which mediate adhesion to 
complement, fibrinogen, immunoglobulin, and 
surfactant A and D[4]. Ability to grow at elevated 
temperature is another virulence factor. Fungi that 
cause systemic infections are able to grow at body 
temperature and even at febrile temperatures of 38-
420C. A. fumigatus is particularly thermophilic, and 
can grow at temperatures of up to 55-770C[5]. HSP 
70 is thought to be required by fungi to adapt to 
high temperatures [6].  
A.fumigatus secretes proteases (serine and aspartic 
protease, metalloprotease) and phospholipases 
which degrade elastin present in lung tissue. The 
serine proteases degrade collagen, fibrin and 
fibrinogen [7]. Production and release of 
degradative enzymes enable them to establish 
disease and disseminate, and also protects from the 
effects of oxidation. A. fumigatus produces three 
catalases; Cat- A associated with conidia, and Cat 
1p and Cat 2p associated with hyphae [4] as well as 
superoxide dismutases (containing Mn, Cu and Zn) 
that protect it from oxidative damage [8].Melanin is 
also synthesised by A. fumigatus from acetate using 
a 6 genes pathway [4].Melanin protects against 
harsh conditions and ROS [8].The ability to obtain 
Fe from the storage or transport forms in the host is 
another virulence factor.A. fumigatus uses three 
mechanisms of Fe uptake; reductase Fe uptake, 
siderophore-mediated Fe uptake and ferrous Fe 
uptake mechanisms [9]. A. fumigatus secretes a 
number of toxins such as aflatoxin and gliotoxin. 
Aflatoxin does not have any bearing on virulence of 
A. fumigatus, it is hepatotoxic and carcinogenic. 
Gliotoxin is immunosuppressive and inhibits 
phagocytosis by macrophages and T-cell activation 
[7]. It also slows ciliary movement thus making it 
difficult for the fungal cells to be swept away, and 
causes damage to the epithelia [10]. Calcineurin acts 
as a sensor forA. fumigatus, it is said to influence the 
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3. DISEASES CAUSED BY 
ASPERGILLUSSPECIES 
(ASPERGILLOSIS) 
The portal of entry in most cases is the respiratory 
tract. Humans inhale conidia in the environment 
which can get to the lung alveoli because of their 
small size and hydrophobic coat (aerodynamics) 
[12]. However, most immunocompetent persons are 
able to eliminate the spores by innate immune 
mechanisms. Those who are at great risk of 
developing disease are people with immune defects 
such as patients with neutropenia, and people with 
neutrophil and macrophage dysfunction. Other 
susceptible hosts are patients on chemotherapy and 
long term corticosteroid therapy, patients with 
haematological malignancies such as leukaemia, 
bone marrow transplant recipients, solid organ 
transplant recipients and AIDS patients. Apart from 
immunosuppression, steroids have been shown to 
accelerate the growth rate and doubling time of A. 
fumigatus [3]. The diseases caused by A. fumigatus 
are invasive aspergillosis, chronic pulmonary 
Aspergillosis (including aspergilloma), and allergic 
bronchopulmonary aspergillosis (ABPA). A. 
fumigatus is also implicated in the exacerbation of 
asthma [13]. 
3.1CHRONIC PULMONARY ASPERGILLOSIS 
(CPA) 
CPAis also known as pulmonary aspergillosis with 
cavities. CPA occurs in immunocompetent people 
who have had previous cavitatry lung diseases, 
with tuberculosis being the underlying disease in 
most cases[14, 15]. About 30-44% of patients with 
CPA had underlying TB [15, 16]. Other 
predisposing diseases are sarcoidosis [17], 
bronchiectasis, pulmonary infarcts, lung abscesses, 
bronchial cysts [18], ABPA, emphysema, prior 
treated lung CA [16] and cavities formed by other 
fungal infections [19, 20]. CPA occurs in different 
forms; chronic cavitatry pulmonary aspergillosis 
(CCPA), chronic fibrotic pulmonary aspergillosis 
(CFPA), and pulmonary aspergilloma. Chronic 
necrotising pulmonary aspergillosis (CNPA) involves 
hyphal invasion of tissues and is thus considered as 
a sub-acute form of IPA, it occurs in people with 
mild impairment of immunity such as defects in 
mannose binding lectin (MBL), diabetes mellitus 
(DM) and corticosteroid use[21, 22]. Patients with 
CCPA have multiple cavities which increase over 
time by expansion or formation of new cavities. 
Pulmonary aspergilloma occurs as fungal balls in 
CCPA. CFPA is the end result of CNPA or more 
commonly untreated CCPA, there is marked 
fibrotic reaction within the cavities [21]. 
In pulmonary aspergilloma, A. fumigatus over 
grows on the surface of these cavities forming a 
spheroidal mass of hyphae with inflammatory cells, 
fibrin, mucous and tissue debris. These appear as 
intracavitatry spherical structures with a 
surrounding area of translucency on radiographs 
[18]. Complex pulmonary aspergilloma may be 
synonymous with CCPA, though not all CCPA 
contain fungal balls [21]. Simple pulmonary 
aspergilloma occur as isolated thin-walled cysts in 
persons who do not have any underlying lung 
disease, this makes up about 18% of pulmonary 
aspergilloma cases [14]. A. fumigatus colonising the 
bronchial tree is said to secrete digestive enzymes 
which creates space for the fungal ball to grow [23]. 
The commonly affected site is the upper lobe, and 
some patients may be asymptomatic with the 
disease picked up during routine chest radiograph. 
It frequently affects middle-aged people with a 
predominance of males [14, 21]. However, 
symptomatic persons present frequently with 
haemoptysis, with bleeding from the bronchial 
arteries that is usually self-limiting [24]. Local 
invasion of these blood vessels or the release of 
endotoxin or trypsin-like proteolytic enzymes is 
said to cause haemoptysis [18]. Recurrent large 
volume haemoptysis is associated with poor 
outcome. Other symptoms are cough, dyspnoea, 
chest pain, malaise, shortness of breath, and weight 
loss [21]. Diagnostic features include radiologic 
demonstration of 1 or more cavities and/or fungal 
balls, precipitating antibodies to A. fumigatus, and 




The outcome of patients with CPA depends on the 
presence and severity of underlying lung condition, 
the fungal balls do not respond to antifungals. 
Amphotericin B and itraconazole show some 
benefits and IFN-γ is used as an adjunct [21]. 
Increasing Aspergillus-specific IgG titre, size and 
number of lesions are associated with poor outcome 
[18]. Treatment is thus surgical involving lobectomy 
or resection [15]; however, there could be 
recurrence [14] and associated post-operative 
complications such as pleural aspergillosis, fistula, 
respiratory failure or disseminated disease [15, 25-
27]. The annual mortality rate of CPA is 15% (range 
5-25%) and patients usually die from respiratory 
failure or pneumonia [18]. Factors which have been 
associated with poor prognosis include severe 
underlying lung disease and recurrent haemoptysis 
[14]. 
 
FIGURE I CHRONIC PULMONARY ASPERGILLOSIS 
Severe bilateral chronic pulmonary aspergillosis with 
the left upper lobe replaced by one large and several 
smaller cavities and a fluid level (which on aspiration 
grew a pure growth of Aspergillusfumigatus). There is 
also extensive disease of the right upper lobe with a 
more consolidation-type appearance, but containing 




ABPA is a severe allergic pulmonary disease seen 
commonly in patients with cystic fibrosis and 
asthma, with an incidence estimated to be about 
2.5% in adults with asthma from five referral 
cohorts[28, 29].  It is a hypersensitivity reaction to 
Aspergillus antigens, about 28% of asthmatic are 
shown to be sensitised to the antigens from studies 
done[30,31]. Sensitisation to Aspergillus antigen 
apart from increasing the risk for ABPA increases 
the severity of asthma in this group of people. 
Among patients with cystic fibrosis the presence of 
atopy predisposes to the development of ABPA 
[32]. ABPA has also been described in people with 
allergic fungal sinusitis [28], chronic granulomatous 
disease and hyper IgE syndrome [34]. 
Central to the pathogenesis of ABPA is an IgE- 
mediated hypersensitivity reaction and specific 
IgG-mediated type III hypersensitivity reaction[35]. 
Impaired mucociliary action in CF, and 
inflammation in the airways in asthma makes the 
inhaled Aspergillus allergens to persist.  Aspergillus 
attaches and grows on the bronchial epithelial cells, 
producing allergens including several proteases 
and these proteases detach the epithelial cells and 
elicit release of pro-inflammatory mediators [36]. 
These mediators cause damage to the airways over 
years resulting in bronchiectasis, and recruitment of 
inflammatory cells [37]. There is also a specific Th-2 
CD4+ response seen in people with ABPA [38]. 
There seem to be some genetic predisposition to 
ABPA as familial clustering has been shown 
amongst asthmatics and cystic fibrosis patient, 
about 5% of ABPA patients showed familial 
clustering in one study [39,40]. The cystic fibrosis 
Trans membrane regulator (CFTR) gene is also 
thought to have an etiologic role in ABPA in cystic 
fibrosis patients[41,42]. 
ABPA presents clinically as worse asthma with 
wheezing, pleuritic chest pain, fever, and 
expectoration of brown mucus plugs [43]. 
Diagnostic criteria of ABPA in asthmatics are 
increased levels of allergen specific IgE and total 
serum IgE (>417kIU/L), pulmonary infiltrates on 
chest radiograph, and proximal bronchiectasis. This 
group of ABPA patients are known as ABPA –
central bronchiectasis. Most ABPA patients also 
have a positive skin reactivity test to Aspergillus 
antigens, increased serum specific IgG antibodies 
and eosinophilia [43, 44]. A second diagnostic 
group of ABPA patients has all features except 
central bronchiectasis; this group is known as 
ABPA-seropositive. The diagnostic criteria for 
ABPA in cystic fibrosis is slightly different, a 
worsening of clinical condition is one of them, 
central bronchiectasis is not a criterion and the total 
serum IgE concentration should be > 1000kIU/L 
[44].  
There are five stages described for ABPA based on 
radiographic infiltrates and total serum IgE; stage I 
is the acute stage with infiltrates in the upper or 
lower lobe involvement and a markedly elevated 
IgE. Stage II is a remission stage without infiltrates 
and a normal or elevated IgE, while stage III is an 
exacerbation stage with features same as the acute 
phase. Patients with infiltrates could also be in stage 
IV when they have corticosteroid –dependent 
asthma, and stage V is the end stage with fibrotic or 
cavitatry lesions [45]. Both oral and inhaled steroids 
are used to reduce the inflammation in ABPA[44]. 
Antifungals such as itraconazole are given 




lung and minimise the production of allergens, 
reducing inflammation, and risk of invasive 
aspergillosis [46,47]. 
3.3SEVERE ASTHMA AND A. FUMIGATUS 
Some patients with asthma tend to have more 
severe symptoms than others, this is characterised 
by prolonged hospital stay and increased use of 
bronchodilators. Fungal sensitisation has been 
linked to severe asthma, although many fungal 
allergens may cause this, Aspergillus allergens are 
important in the exacerbation of asthma [13,48]. A. 
fumigatus is a major indoor aeroallergen [49], with 
proteases which are implicated in the 
hypersensitivity reactions in the lung [50]. This 
Aspergillus protease has also been shown to cause 
damage to the airway epithelium, and release of 
inflammatory cytokines-IL6 and IL8 [51]. Aspergillus 
specific Serum IgG antibody level which is a 
diagnostic feature for aspergillosis was found to be 
associated with severe asthma [52]. 
3.4 INVASIVE ASPERGILLOSIS 
Invasive aspergillosis (IA) commonly affects people 
with neutropenia with the risk for IA more after the 
third week of the neutropenia. It is seen in 
immunosuppressed people such as those on 
chemotherapy and/or long-term steroids, recipients 
of bone marrow transplant or solid organ 
transplant, with those who receive heart and lung 
transplant at an increased risk, and patients with 
hematologic malignancies such as leukaemia.  IA is 
also common in persons with congenital 
immunodeficiency disorders such as CGD and 
acquired immunodeficiency disorders [53-55]. It is 
rare in immunocompetent hosts. Invasive 
aspergillosis is responsible for 30% of fungal 
infections seen in cancer patients [56]. Despite 
treatment, the mortality rate of IA was 75-90% in 
leukaemia patients in the 1980s and 1990’s but has 
now fallen to ~30%  [1,2] and up to 25% of 
leukaemia patients develop IA [57-59]. This makes 
it a major cause of death in leukaemia patients, and 
also in bone marrow or organ transplant recipients.  
There are four groups of IA; acute or sub-acute 
invasive pulmonary aspergillosis, tracheobronchitis 
and obstructive bronchial disease, invasive 
Aspergillus sinusitis, and disseminated disease. 
These occur almost exclusively in 
immunocompromised patients, with the portal of 
entry being the respiratory tract. Invasive 
aspergillosis can also occur by direct invasion of 
wounds and burns on skin, the cornea (keratitis) or 
by association with in-dwelling catheters [3, 54] 
Invasive pulmonary aspergillosis (IPA) is the most 
common type of IA (80-90%) [3], the acute type 
being more common than the sub-acute type. There 
are two pathologic entities of IPA; angio-invasive or 
non-angio-invasive. The angio-invasive is seen in 
neutropenic patients and manifests as vascular 
invasion by hyphal elements with coagulative 
necrosis and haemorrhage. While in non-angio-
invasive IPA seen in non-neutropenic patients, 
there is a pyogranulomatous inflammation and 
necrosis without evidence of vascular invasion [60]. 
IPA has been increasing in incidence, with a 
prevalence of about 56% of all invasive mycoses 
found on autopsy[57, 61]. Neutropenia is a strong 
risk factor, the degree and duration contributing 
greatly to the risk of developing IPA [53]. Patients 
with leukaemia have neutropenia, while those with 
CGD have dysfunctional neutrophils. Neutropenia, 
immunosuppression and prolonged hospital stay 
make bone marrow transplant recipients at great 
risk; about 5% of bone marrow recipients develop 
IPA and this risk is higher with allogeneic stem cell 
transplantation[59, 62, 63]. Solid organ 
transplantation especially, that of heart and lung 
carries a high risk for IPA, with an incidence of 19-
26% [59, 63]. 
Sub-acute IPA occurs in people with AIDS, CGD 
[64], and in apparently immunocompetent persons 
especially those with chronic obstructive 
pulmonary disease (COPD) [65]. Low CD4 count 
(<50 cells/mm3), co-existing neutropenia and 
steroid therapy are associated risk factors for AIDS 
patients [66, 67].  COPD patients are susceptible 
because of long term therapy with steroids and 
other factors resulting from their treatment and 
hospital stay [68]. Steroids impair the phagocytic 
functions of neutrophils and macrophages [3]. Co-
morbidities such as DM, alcoholism, malnutrition 
and asthma also predispose COPD patients to sub-
acute IPA [69]. 
The symptoms of IPA depend on the immune 
status of the host; immunocompetent individuals 
have more prominent symptoms which may last 
over weeks or months, while immunocompromised 
persons tend to have less symptoms but rapid 
progression of disease. Symptoms are non-specific; 
cough dyspnoea, pleuritic chest pain, haemoptysis 
and fever that do not subside with antibiotics use. 
Fever is however absent in patients on 
corticosteroid therapy, and patients with chronic 
IPA also have malaise and weight loss [51]. AIDS 
patients with IPA have an increased incidence of 
tracheobronchial involvement in addition to the 
symptoms described [67,70]. 
Early diagnosis and prompt use of antifungal 
agents such as amphotericin B or voriconazole 
could reduce mortality rate. However, rapid 
diagnosis is difficult and there are treatment 
limitations with amphotericin B and voriconazole 
due to toxicities [71, 72].  Chest radiograph in the 




the hallmark of diagnosis is histological 
examination of lung tissue [73]. Detection of 
Aspergillus antigens such as galactomannan in body 
fluids can diagnose the disease even before the 
appearance of clinical signs and symptoms [74]. 
Bronchoscopy and bronchoaveolar lavage (BAL) is 
done to obtain fluids for culture and detection of 
Aspergillus antigens and PCR[60,75], especially in 
patients with diffuse lung involvement [69]. 
Prognosis of IPA also depends on removal of the 
underlying defects, for example, restoration of 
neutrophil counts and function. 
Immunomodulatory therapy such as colony-
stimulating factors and interferon-γ could be used 
as adjuvant therapy; IFN-γ was shown to accelerate 
cure without clinical toxicity in renal transplant 
recipients with IPA [76, 77]. 
Aspergillus tracheobronchitis is isolated to the 
tracheobronchial tree. The risk factors are same as 
IPA, but tracheobronchitis is more common in AIDS 
patients [67, 70] and lung transplant recipients [78]. 
In about a quarter of patients, no apparent 
immunosuppression is observed [70].There are 
three forms of the disease; an obstructive type with 
limited inflammation but with production of thick 
mucus plugs full of Aspergillus, the ulcerative type 
which affects a limited area of the tracheobronchial 
tree and is common in recipients of lung transplant, 
and the pseudomembranous type with extensive 
inflammation of the membranes [79] .Most patients 
present with symptoms of cough, fever, chest pain, 
dyspnoea and haemoptysis[3, 69]. 
Mortality is high (78%) especially in the 
pseudomembranous and obstructive types, patients 
die from respiratory failure[3, 80]. Dissemination or 
tracheal perforation may complicate the disease 3[6]. 
Diagnosis is based on characteristic findings on 
bronchoscopy and microscopic demonstration of 
the fungus from respiratory specimens. Outcome is 
good with antifungal therapy, especially with the 
ulcerative type [69]. 
Invasive Aspergillus sinusitis may manifest as 
acute rhinosinusitis, chronic sinusitis or as a 
paranasal Aspergillus granuloma[3]. It is very 
uncommon in patients who receive solid organ 
transplants, but the acute rhinosinusitis is common in 
bone marrow transplant recipients, and patients 
with neutropenia [81,82].  A. flavus is implicated 
more often in invasive Aspergillus sinusitis [83]. 
Common sites affected are the maxillary, ethmoid 
and mastoid sinuses. Patients present with fever, 
local pain, nasal discharge, epistaxis and headaches. 
It can occur alone or with pulmonary aspergillosis, 
but CNS involvement is quite common [3,84] .The 
disease can spread to surrounding structures such 
as the palate, orbit or brain, and this is usually 
fatal[85, 86].  Diagnosis is by demonstration of fluid 
opacities in the sinuses on CT-scan and a positive 
culture. Patients are usually managed with 
amphotericin B and voriconazole [3], surgery is also 
important [87]. 
Chronic Aspergillus sinusitis occurs in 
immunocompetent persons or those with mild 
suppression in immunity such as diabetics, 
alcoholics and people living with HIV [62, 87-89]. 
The mucosa and other tissues are invaded by the 
Aspergillus hyphae, and the bone may be destroyed. 
Symptoms include diplopia and visual impairment, 
headaches, and nasal stuffiness; fever is absent[3, 
69]. Aspergillus sinusitis may be complicated by 
osteomyelitis [90], and brain abscess or stroke if the 
sphenoid sinus is involved [91]. Radiological 
features (similar to that seen with acute form) and 
positive culture are diagnostic. Treatment involves 
antifungal therapy and surgical debridement, the 
disease usually runs a chronic course and may 
relapse [3]. 
Disseminated aspergillosis involves the central 
nervous system in most cases but also affects organs 
such as the eye, kidney, skin and heart[92, 93]. 
About 10-40% of bone marrow transplant recipients 
are affected, and at autopsy 6-15% of patients who 
died from haematological malignancies had CNS 
aspergillosis. CNS aspergillosis is also common in 
HIV patients ; and neutropenia and steroid use are 
additional risk factors [93].The disease progresses 





on of the retina of the eye following dissemination from 
the lung.© LIFE @http://life-worldwide.org 
Cutaneous aspergillosis may occur with 
disseminated invasive aspergillosis, but it can also 
occur directly at intravenous catheter sites in 
neutropenic patients [3]. Cutaneous aspergillosis 
can also arise from an adjacent affected tissue such 




primary cutaneous aspergillosis [94]. It has been 
reported in diabetic patients and apparently 
immunocompetent persons [95].The lesions are 
usually distributed over areas of terminal 
circulation such as the limbs [96].Aspergillus can 
also cause dermatitis in premature new-borns [97]; 
it also invades burns and surgical wounds [3]. 
4. CONCLUSION                                         
The global burden of aspergillosis 
 Aspergillosis as described are important causes of 
morbidity and mortality worldwide, affecting 
mostly the immunosuppressed.  The incidences and 
associated mortalities of invasive aspergillosis have 
increased as a result of advancement in treatments, 
and cancers.  Prolong hospital stay, frequent 
hospital visits, prolong duration of treatment and 
high costs of antifungals are all factors that make 
aspergillosis to exert a huge financial burden on the 
economy.  Aspergillosis complicating other chronic 
medical conditions increases the morbidity and 
mortality from these conditions.  Coupled to these 
is the difficulty with diagnosis especially in 
developing nations. 
About 10million people are at risk of aspergillosis, 
and 50% would die even with treatment. Most 
invasive diseases are in stem cell and organ 
transplant recipients, greater than 75,000 people 
receive these transplants annually with about 10% 
at risk of developing invasive disease [98] As 
discussed, ABPA affects asthmatics and people with 
cystic fibrosis. About 4 million out of the 193 
million with asthma are affected, while 15% of 
people with cystic fibrosis develop ABPA. Chronic 
pulmonary aspergillosis has a worldwide 
prevalence of about 3million, about a third of these 
cases occur in the setting of previous tuberculosis 
infection [16]. This is of importance as the rate of 
tuberculosis seems to be on the increase with AIDS 
especially in sub-Saharan Africa.  Allergic fungal 
sinusitis and rhinitis may not be associated with 
mortality, but they affect the quality of life with 
significant loss of work or school days and reduced 
performance. They affect 12 million people at any 
time [99]. Fungal eye infections affect 1million 
people worldwide, causing about 10% of avoidable 
blindness [100]. 
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